XNAS · FENC
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Fennec Pharmaceuticals Inc. Common Stock

Fennec Pharmaceuticals Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$10.33
Card
Relationship Map

Follow $FENC

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $FENC by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
FENC
Fennec Pharmaceuticals Inc. Common Stock
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

55/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is FENC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading FENC catalysts
About Fennec Pharmaceuticals Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2002
Employees
35
Country
US

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$10.33
Last session
Day high
$10.33
Last session
Day low
$10.33
Last session
Previous close
$10.33
52W high
$12.78
-19.17% from high
52W low
$5.77
65% of range
Market cap
$362.2M
EPS
$-0.0700
Beta
0.92
Shares out
35.1M
Avg volume
219.2K
VWAP
$10.33
Last session
Price history computed in-house
1W
-2.59%
1M
-16.08%
3M
-3.46%
1Y
+6.83%
YTD
+34.16%
SMA 50 $11.13 · below
SMA 200 $8.92 · above
52W position 65%

FENC overview

Veridion Score
55
Registered · 2026-10-01
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around FENC.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading FENC Form 4 filings
Public disclosures

Congress activity in FENC

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for FENC in the cached public ledger.

Federal contracts

FENC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for FENC in this window.
Lobbying spend

FENC lobbying filings, year to date.

Registered lobbying filings matched to Fennec Pharmaceuticals Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for FENC in this window.
Loading news for FENC
Analyst ratings
Sovereign unlock shows live analyst consensus for FENC.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.